

[New Drug Approvals](#)

Generic Name (Trade Name—Company)

May 27, 2011

Uses/Notes

Treatment of fecal incontinence in adult patients who have failed previous therapies such as modifications in diet, fiber therapy, or antitmotility medications

Dextranomer microspheres and stabilized sodium hyaluronate

(Solesta—Oceana Therapeutics)

Injectable gel device for treatment of fecal incontinence

[Solesta](#) 1 mL injectable gel consists of dextranomer microspheres (50 mg/mL) and stabilized sodium hyaluronate (15 mg/mL) in a phosphate-buffered 0.9% sodium chloride solution. It is injected into the deep submucosal layer in the proximal part of the high pressure zone of the anal canal. A total of four submucosal injections are administered at each treatment session. The injections are designed to build up tissue in that area so that the opening of the anus narrows allowing patients to have better control of their muscles. Only physicians experienced in performing anorectal procedures and who have successfully completed the Solesta injection procedure training program can administer the gel.

Source URL:

<http://aphanet.org/injectable-gel-device-treatment-fecal-incontinence>

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.